An inhibitor of IDO1 and TDO
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

NLG-919 analog

Item No. 21509

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
α-cyclohexyl-5H-imidazo[5,1-a]isoindole-5-ethanol
CAS Number
1402836-58-1
Synonyms
  • GDC-0919
Molecular Formula
C18H22N2O
Formula Weight
282.4
Purity
≥98% (mixture of enantiomers)
Formulation
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 16 mg/mlDMSO: 16 mg/mlDMSO:PBS (pH 7.2) (1:10): 0.3 mg/mlEthanol: 14 mg/ml
λmax
213, 274 nm
SMILES
OC(C1CCCCC1)CC2N3C(C4=CC=CC=C42)=CN=C3
InChi Code
InChI=1S/C18H22N2O/c21-18(13-6-2-1-3-7-13)10-16-14-8-4-5-9-15(14)17-11-19-12-20(16)17/h4-5,8-9,11-13,16,18,21H,1-3,6-7,10H2
InChi Key
YTRRAUACYORZLX-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $41

    Add

    5 mg

    $108

    Add

    10 mg

    $196

    Add

    25 mg

    $437

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    NLG-919 analog is an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO; IC50s = 79 and 25 nM, respectively, in cell-free assays).1 It decreases kynurenine levels in cells expressing human IDO1 (EC50 = 83 nM).2 NLG-919 analog (0.025-1 µM) decreases the percentage of anti-CD3- and anti-CD28-activated Jurkat T cells that are positive for programmed cell death protein 1 (PD-1).3 In vivo, NLG-919 analog (100 mg/kg) decreases tumor volume and weight and the percentage of intratumoral CD4+CD25+ regulatory T cells (Tregs) in a B16/F10 murine melanoma model when administered alone or in combination with paclitaxel (Item No. 10461).4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Seegers, N., van Doornmalen, A.M., Uitdehaag, J.C., et al. High-throughput fluorescence-based screening assays for tryptophan-catabolizing enzymes. J. Biomol. Screen. 19(9), 1266-1274 (2014).

    2. Kumar, S., Waldo, J.P., Jaipuri, F.A., et al. Discovery of clinical candidate (1R,4 r)-4-((R)-2-((S)-6-fluoro-5 H-imidazo[5,1- a]isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol (navoximod), a potent and selective inhibitor of indoleamine 2,3-dioxygenase 1. J. Med. Chem. 62(14), 6705-3766 (2019).

    3. Qin, R., Zhao, C., Wang, C.J., et al. Tryptophan potentiates CD8+ T cells against cancer cells by TRIP12 tryptophanylation and surface PD-1 downregulation. J. Immunother. Cancer 9(7), e002840 (2021).

    4. Meng, X., Du, G., Ye, L., et al. Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model. Int. J. Immunopathol. Pharmacol. 30(3), 215-226 (2017).